Table 1.
Patient characteristics of FAME intervention and control groups at baseline
| Patient Group | FAME Group (N = 236) |
Control Group (N = 236) |
P value |
|---|---|---|---|
| Age, mean (SD) | 73.2 (6.1) | 73.3 (6.0) | 0.79 |
| Sex=Male | 94.9 | 96.6 | 0.38 |
| Race, White | 65.3 | 68.8 | 0.72 |
| Anxiety | 14.4 | 16.2 | 0.58 |
| Arrhythmia | 16.5 | 21.4 | 0.18 |
| Congestive Health Failure | 5.5 | 8.6 | 0.20 |
| Chronic pain | 46.6 | 33.8 | 0.005 |
| Cognitive Impairment | 15.7 | 11.1 | 0.15 |
| Cardiovascular Disease | 14.4 | 29.5 | <0.0001 |
| Depression | 46.6 | 50.0 | 0.46 |
| Diabetes | 44.1 | 43.2 | 0.84 |
| Hypertension | 72.5 | 83.3 | 0.005 |
| Insomnia | 17.0 | 37.2 | <0.0001 |
| Other Psychiatric Conditions | 14.0 | 38.9 | <0.0001 |
| Post-traumatic Stress Disorder | 42.8 | 38.5 | 0.34 |
| Falls in last 3 months | 24.2 | ||
| % with 1 or more meds in each medication class | |||
| Alpha-adrenergic Antagonists | 40.7 | 45.3 | 0.31 |
| Anticholinergic | 61.4 | 50.0 | 0.012 |
| Antidepressants | 69.1 | 79.8 | 0.69 |
| Antipsychotic | 17.0 | 13.6 | 0.31 |
| Benzodiazepine | 22.0 | 16.5 | 0.13 |
| Diuretics | 26.3 | 24.6 | 0.67 |
| Gabapentinoids | 52.5 | 48.3 | 0.36 |
| Hypoglycemic | 34.8 | 28.8 | 0.17 |
| Sedative-Hypnotic | 14 | 14.8 | 0.79 |